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ABSTRACT
Introduction: Misidentification of the extrahepatic bile
duct anatomy during laparoscopic cholecystectomy
(LC) is the main cause of bile duct injury. Easier
intraoperative recognition of the biliary anatomy may
be accomplished by using near-infrared fluorescence
(NIRF) imaging after an intravenous injection of
indocyanine green (ICG). Promising results were
reported for successful intraoperative identification of
the extrahepatic bile ducts compared to conventional
laparoscopic imaging. However, routine use of ICG
fluorescence laparoscopy has not gained wide clinical
acceptance yet due to a lack of high-quality clinical
data. Therefore, this multicentre randomised clinical
study was designed to assess the potential added
value of the NIRF imaging technique during LC.
Methods and analysis: A multicentre, randomised
controlled clinical trial will be carried out to assess the
use of NIRF imaging in LC. In total, 308 patients
scheduled for an elective LC will be included. These
patients will be randomised into a NIRF imaging
laparoscopic cholecystectomy (NIRF-LC) group and a
conventional laparoscopic cholecystectomy (CLC)
group. The primary end point is time to ‘critical view of
safety’ (CVS). Secondary end points are ‘time to
identification of the cystic duct (CD), of the common
bile duct, the transition of CD in the gallbladder and
the transition of the cystic artery in the gallbladder,
these all during dissection of CVS’; ‘total surgical
time’; ‘intraoperative bile leakage from the gallbladder
or cystic duct’; ‘bile duct injury’; ‘postoperative length
of stay’, ‘complications due to the injected ICG’;
‘conversion to open cholecystectomy’; ‘postoperative
complications (until 90 days postoperatively)’ and
‘cost-minimisation’.
Ethics and dissemination: The protocol has been
approved by the Medical Ethical Committee of
Maastricht University Medical Center/Maastricht
University; the trial has been registered at ClinicalTrials.
gov. The findings of this study will be disseminated
widely through peer-reviewed publications and
conference presentations.
Trial registration number: NCT02558556.
INTRODUCTION
Laparoscopic cholecystectomy (LC) is the
most commonly performed laparoscopic pro-
cedure in the Netherlands, with almost
23 000 procedures annually.1 Bile duct injury
during this procedure is rare with an inci-
dence of 0.3–0.7%.2–5 However, when bile
duct injury or vascular injury is present, it
results in signiﬁcant clinical relevant morbid-
ity and mortality, lower quality of life and
extra costs.6–10 Bile duct injury will generally
lead to bile leakage and abdominal sepsis
and can lead to bile duct obstruction with
Strengths and limitations of this study
▪ This study is a multicentre, randomised, con-
trolled trial.
▪ The study addresses a clinically important topic:
safety of laparoscopic cholecystectomy.
▪ Operative end points will be assessed in a dual
manner: peroperatively and also by an expert
panel postoperatively based on video analysis.
▪ A more preferable primary end point would have
been ‘bile duct injury’; however, this is not
achievable since very large sample sizes would
be required for sufficient power.
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obstructive jaundice eventually leading to orthotropic
liver transplantation or both.7 Late recognition and
management of bile duct injuries can lead to severe
deterioration in the patient’s condition, progressing to
biliary peritonitis, sepsis, multiorgan failure and eventu-
ally death. Therefore, early recognition and treatment is
important.7 11 Misidentiﬁcation of the extrahepatic bile
duct anatomy during LC is the main cause of bile duct
injury.12
To reduce this risk of bile duct injury, the critical view
of safety (CVS) technique was introduced by Strasberg
in 1995.13 A recent Society of American Gastrointestinal
and Endoscopic Surgeons (SAGES) expert Delphi con-
sensus deemed the CVS as being the most important
factor for overall safety,14 in accordance with the current
Dutch Surgical Society Guideline for Laparoscopic
Cholecystectomy.15
To establish CVS, two observation windows need to be
created: one window between the cystic artery (CA),
cystic duct (CD) and gallbladder and another between
the CA, gallbladder and liver (see ﬁgure 1A,B). The
CVS technique is especially aimed at mobilising the gall-
bladder neck from the liver, in order to obtain a circum-
ferential identiﬁcation of the transition of the CD into
the gallbladder. Nowadays, the CVS technique is the
gold standard to perform a safe cholecystectomy with
identiﬁcation of the vital structures such as the CD.16–20
According to a Dutch nationwide survey in 2011, 97.6%
of the Dutch surgeons use the CVS technique.21
However, according to a recent study by Nijssen et al,22
only in 10% of the laparoscopic cholecystectomies CVS
is actually established. This could mean that it is more
difﬁcult to establish CVS than thought before, thus
resulting in more bile duct injury than necessary.
Nowadays, there are several imaging techniques, such
as intraoperative cholangiography (IOC) and near-
infrared ﬂuorescence (NIRF) imaging, to identify the
relevant anatomical structures easier. IOC has been
advised to reduce the risk of bile duct injury.2 16 23
However, this radiological imaging of the biliary tree is
not adopted worldwide in standard LC, as the procedure
takes time, involves radiation exposure and requires add-
itional equipment and manpower. Moreover, the inter-
pretation of an intraoperative cholangiogram with
potentially distorted anatomy clearly depends on the
expertise of the surgeon. Therefore, worldwide consen-
sus about implementation of IOC is still lacking.24
NIRF imaging after intravenous injection of indocya-
nine green (ICG) is a promising new technique for
easier intraoperative recognition of the biliary
anatomy.25 26 ICG is cleared quickly and exclusively by
the liver after intravenous administration and has a very
well-known pharmacokinetic and safety proﬁle. Neither
radiological support nor additional intervention such as
opening the cystic or common bile duct (CBD) is
required, making it an easy, real-time and ﬂexible tech-
nique to use during surgery. By real-time identiﬁcation
of the vital structures being the CD and CBD within the
already adapted CVS technique, it may improve the
outcome of LC.16 27 28 NIRF imaging using ICG has
been evaluated in various animal models29–31 and in
open, laparoscopic and single-incision laparoscopic
cholecystectomies.30 32–34 Promising results were pre-
sented for safe and successful intraoperative
Figure 1 (A) CVS anterior view
and (B) CVS posterior view. Two
windows are created. One
window between the cystic artery,
cystic duct and gallbladder, the
other between the CA,
gallbladder and liver. CA, cystic
artery; CVS, critical view of
safety.
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identiﬁcation of the CBD and the CD, compared to con-
ventional laparoscopic imaging. Furthermore, a clinical
study (n=30) showed that the NIRF imaging technique
provided signiﬁcantly earlier identiﬁcation of the extra-
hepatic bile ducts during the CVS dissection phase: up
to 10 min earlier identiﬁcation of the CD and CBD
could be obtained.35 Real-time imaging of the hepatic
and cystic arteries was also achieved when a repeated
dose of ICG was given.35–37
Despite these encouraging results derived from clin-
ical feasibility studies, the routine use of ICG ﬂuores-
cence laparoscopy has not gained wide clinical
acceptance yet due to a lack of high-quality clinical data.
Therefore, a multicentre randomised clinical study was
designed to assess the added value of the NIRF imaging
technique during LC. The ultimate goal of this tech-
nique is to perform a safer procedure leading to a
reduction in vascular and bile duct injuries. The primary
objective of the present study is to evaluate whether
earlier establishment of CVS can be obtained using the
NIRF imaging technique during LC.
METHODS AND ANALYSIS
Primary aim
The main objective of the study is to evaluate whether
earlier establishment of the CVS can be obtained using
the NIRF imaging technique during elective LC, by
applying NIRF imaging as an adjunct to conventional
laparoscopic imaging versus conventional laparoscopic
imaging alone.
Hypothesis
It is hypothesised that standard application of NIRF
imaging during LC will result in establishment of CVS at
least 5 min earlier and with more certainty regarding
visualisation of biliary anatomy when compared to con-
ventional laparoscopic imaging alone.
Study design
This multicentre randomised controlled clinical trial
includes two randomisation arms: a NIRF-LC (laparo-
scopic cholecystectomy) group—this group of patients
will undergo NIRF cholangiography assisted laparo-
scopic cholecystectomy and a conventional laparoscopic
cholecystectomy (CLC) control group—this group will
undergo CLC.
Setting
This study will initially take place in ﬁve large teaching
hospitals in the Netherlands, of which three are
Academic Medical Centers. After the study in these
centres has started, international centres will be
included.
Participants
In the FALCON trial, a total of 308 patients will be
included at the Departments of Surgery of the
participating centres. The centres will be supported by
the trial coordinator ( JvdB) and by the Clinical Trial
Center Maastricht (CTCM) (see also under the ‘data
monitoring’ section). Further, no additional strategies
for achieving adequate participant enrolment to reach
the target sample size are considered necessary, as LC is
a commonly performed surgery.
Sample size calculation
The number of 308 participants is based on pilot
data,35 38 where the identiﬁcation of the CD and CBD
was established, respectively, 11 and 10 min earlier using
ﬂuorescence laparoscopic imaging compared to conven-
tional laparoscopic imaging. A sample size of 131 for
each randomisation arm has been calculated to detect a
reduction in ‘time to establishment of CVS’ of at least
5 min with a power of 80% and an α of 0.05 (95% CI).
Assuming a withdrawal rate of 15% (due to usual
reasons for dropout in combination with technical difﬁ-
culties concerning the video recordings) during the
trial, we will require a total of 308 (n=2×131+15%).
All patients (age >18 years) scheduled for an elective
LC and meeting the inclusion criteria will be suitable
for inclusion.
Inclusion criteria
The inclusion criteria are as follows: male and female
patients, aged 18 years and above, scheduled for elective
LC, with normal liver and renal function, no hyper-
sensitivity for iodine or ICG, able to understand the
nature of the study procedures, willing to participate
and give written informed consent and Physical Status
Classiﬁcation of ASA I/ASA II.
Exclusion criteria
The exclusion criteria are as follows: age <18 years, liver
or renal insufﬁciency, known iodine or ICG hypersensi-
tivity, pregnancy or breastfeeding, not able to under-
stand the nature of the study procedure and a Physical
Status Classiﬁcation of ASA III and above.
Participants can leave the study at any time for any
reason if they wish to do so without any consequences.
The investigator can decide to withdraw a participant
from the study for urgent medical reasons. Conversion
to open cholecystectomy, before CVS is established, is a
reason for study withdrawal. Furthermore, if the video
recordings of the laparoscopic procedure were not suc-
cessful, the procedure will be unsuitable for analysis of
all predeﬁned end points. There are no other speciﬁc
criteria for withdrawal. In case of withdrawal, partici-
pants will be replaced to achieve the calculated sample
size. All inclusions will be analysed on an intention-
to-treat basis.
Randomisation
All included patients will be randomised centrally using
block randomisation with sealed envelopes and stratiﬁca-
tion per participating centre. After signing the informed
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consent form, the next sealed envelope in line will be
opened by the coordinating investigator. There will be
no blinding of patients or surgeons.
Intervention
The CLC group will undergo conventional laparoscopic
cholecystectomy. The NIRF-LC group will undergo near-
infrared ﬂuorescence cholangiography using a laparo-
scopic NIRF imaging system (Karl Storz GmbH,
Tuttlingen, Germany). To obtain ﬂuorescence imaging
of the biliary tract and CA, a NIRF contrast agent will be
administered. Directly after the induction of anaesthesia,
2.5 mg of ICG (2.5 mg/mL; Diagnostic Green,
Aschheim, Germany) will be given intravenously. A
repeat injection of 2.5 mg will be administered for con-
comitant arterial and biliary ﬂuorescence delineation
after achievement of CVS.
Outcome measures
The primary outcome measure is time to identiﬁcation
of CVS. This end point is used as a surrogate for bile
duct identiﬁcation without surgical exploration. CVS is
established if the following three criteria are met:
1. Mobilisation of the gallbladder infundibulum for
one-third of the length of the gallbladder from the
liver bed.
2. Circumferential exposure of the CD and conﬁrm-
ation of its transition in the gallbladder.
3. Circumferential exposure of the CA and conﬁrm-
ation of its transition in the gallbladder.
Secondary outcome measures are listed in table 1.
Data collection
Intraoperatively, a case report form will be ﬁlled in. A
structure is scored as ‘identiﬁed’ if its localisation is con-
ﬁrmed with great certainty by the experienced surgeon.
The attending surgeon will be consulted to decide
whether he believes CVS is established.
In accordance with regular care, all laparoscopic surgi-
cal procedures will be digitally recorded. An expert
panel, consisting of three highly experienced laparo-
scopic surgeons, will analyse the data using video
Table 1 Secondary outcome measures
Outcome measure Definition
Time until identification of the CD Time in minutes
Time until identification of CBD Time in minutes
Time until identification of the transition of CD into
the gallbladder
Time in minutes
Time until identification of the transition of the CA
into the gallbladder
Time in minutes
Total surgical time Time in minutes from skin incision to the end of skin closure
Visualisation of CVS and visualisation of the
transition of the CD and CA into the gallbladder
Time in minutes
Intraoperative bile leakage from the gallbladder or
CD
Visualised bile leakage or spill during surgery
Bile duct injury Any injury to the main biliary tree; will be classified using the
Strasberg Classification System13
Type A: injury to the CD or from minor hepatic ducts draining the liver
bed
Type B: occlusion of biliary tree, commonly aberrant right hepatic
duct(s)
Type C: transection without ligation of aberrant right hepatic duct(s)
Type D: lateral injury to a major bile duct
Type E:1–5 injury to the main hepatic duct; classified according to level
of injury
Postoperative length of hospital stay Duration from date of admission (included) to date of discharge
(included)
Complications due to injected contrast agent Any complication potentially caused by injected ICG
Conversion to open cholecystectomy Laparoscopic approach converted to an open operation, or in which an
abdominal incision to assist the procedure was needed
90-day all-cause postoperative complications Any complication, up to 90 days, described by the Clavien-Dindo
classification of postoperative complications.39 Specific attention to bile
leak, CBD injury, wound infection, intra-abdominal collection,
pancreatitis, CBD stones, ICU/HDU readmissions; prospectively
assessed during admission; thereafter immediately to be reported to
study coordinator
Cost minimisation Difference in costs (in Euros) between conventional LC and NIRF-LC
CA, cystic artery; CBD, common bile duct; CD, cystic duct; CVS, critical view of safety; LC, laparoscopic cholecystectomy; NIRF, near-infrared
fluorescence.
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recordings: time until identiﬁcation of the CD and of its
transition into the gallbladder; time until identiﬁcation
of the CA and its transition into the gallbladder during
dissection of CVS and when and whether CVS is estab-
lished. Eventually, all ﬁve observers (the surgeon or sur-
gical trainee, PhD researcher or local researcher during
the operation and the three postoperative observers)
will individually assess the above-mentioned end points.
The mean values of these ﬁve assessments will be used
for each of the end points. All clinical data are prospect-
ively registered in a database.
OsiriX V.5.5.1. Imaging Software (Prixmeo, Geneva,
Switzerland) will be used for objective assessment of the
degree of ﬂuorescence illumination in the extrahepatic
bile ducts. The ﬂuorescence images will be analysed by
determining the target-to-background ratio (TBR). TBR
is deﬁned as the mean ﬂuorescence intensity (FI) of two
point regions of interest (ROIs) in the target (ie, CBD,
CD or CA) minus the mean FI of two background (BG)
ROIs in the liver hilum, divided by the mean FI of the
two background ROIs in the liver hilum; that is TBR=(FI
of target−FI of BG)/FI of BG.
The costs made in the two groups will be compared,
resulting in a cost-minimisation analysis. This analysis
will include the costs made by using the operation
theatre in terms of ﬂuorescence laparoscopy equipment,
the ﬂuorescent dye ICG, morbidity, mortality and post-
operative hospital stay.
In ﬁgure 2, a ﬂow chart of the study procedure for the
NIRF-LC group and the CLC-group is presented.
Data validation and management
Patient data will be anonymously registered and analysed
by comparing NIRF-LC with CLC. Only the investigators
will have access to the patient data after informed
consent is given.
Study timeline
In ﬁgure 3, the study timeline is presented. From
January 2016 until January 2018, data will be collected;
in September 2016, March 2017, September 2017 and
March 2018, the expert panel will evaluate the video
material for end points; around July 2018, data analysis
is expected to be complete.
Participants will be informed about the study during
their preoperative visit to the outpatient clinic.
Thereafter, patients have at least a week to consider par-
ticipation in the study. During their elective surgery, the
near-infrared ﬂuorescence laparoscopy will be used if
the patient is randomised in the NIRF-LC group. After
surgery, a 90-day follow-up period follows, and then pos-
sible complications will be evaluated.
Statistical analysis
For statistical analysis, the most recent version of SPSS
(IBM, Armonk, New York, USA) will be used. Baseline
characteristics such as patient clinical history (including
previous surgery), age, body mass index and indication for
the procedure will be recorded and compared between
the intervention (NIRF-LC) and control groups (CLC).
Categorical baseline variables will be compared using a χ2
test, while numerical variables will be compared by the
independent sample t-test or the Mann-Whitney U test,
depending on the distribution.
The primary outcome measure, namely, time until
establishment of CVS, will be given in minutes, with a
mean and SD. A linear regression analysis will be
applied for determination of possible signiﬁcant differ-
ences between the time measurements, therewith com-
paring the NIRF-LC group to the CLC group. This will
be conducted to determine whether a reduction in time
can in fact be achieved using the NIRF imaging tech-
nique compared to CLC.
All numerical secondary outcomes such as time until
visualisation of CD and CA will be analysed using a linear
regression model. In case of missing values, a Cox regres-
sion analysis will be performed. Missing values can occur
especially in the postoperative analysis by the expert panel,
when the panel concludes that, contrary to the opinion
of the operating team, actually no CVS was obtained or
that the transition of the CD or CA in the gallbladder
had actually not been properly identiﬁed. All categorical
secondary outcomes such as bile duct injury and conver-
sion to open surgery will be analysed with a logistic
regression model.
Data monitoring
An independent data monitoring committee will
monitor the study procedures and data management.
This team consists of independent and certiﬁed persons
from the CTCM. No interim analysis will be performed.
Adverse events and serious adverse events will be cen-
trally reported in the online database, toetsingonline.nl.
ETHICS AND DISSEMINATION
The proposed study is approved by the Medical
Ethics committee of Maastricht University Medical
Center/Maastricht University. Possible protocol amend-
ments will be sent to the Medical Ethics Committee of
Maastricht University Medical Center/Maastricht
University. After approval, the changes will be communi-
cated on clinicaltrials.gov and to the relevant parties.
Is there scientific and clinical value in conducting this
study?
Despite the promising results from previous feasibility
studies, a lack of solid clinical data precludes wide clin-
ical acceptance of the routine use of ICG ﬂuorescence
laparoscopy. This multicentre randomised clinical study
can provide such data.
Risk–benefit assessment
There are no additional risks accompanied by the lap-
aroscopic NIRF imaging systems, compared to conven-
tional laparoscopic imaging. The gifts of ICG are the
van den Bos J, et al. BMJ Open 2016;6:e011668. doi:10.1136/bmjopen-2016-011668 5
Open Access
group.bmj.com on May 30, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
only additional (minimally) invasive interventions for
the patient. ICG preparations can, in very rare cases,
cause nausea and anaphylactoid or anaphylactic reac-
tions (<1:10 000). Patients with terminal renal insufﬁ-
ciency seem to be more prone for such an anaphylactic
reaction. Estimated death due to anaphylaxis is reported
as <1 per 330 000.40–43 Symptoms include anxiety,
feeling of warmth, pruritus, urticaria, acceleration of
heart rate, decrease in blood pressure, shortness of
breath, bronchospasm, ﬂushing, cardiac arrest, laryngos-
pasm, facial oedema and nausea. Together with the ana-
phylactoid reaction, hypereosinophilia may occur. If,
contrary to expectations, symptoms of anaphylaxis occur,
the following measures will be taken: stop further
Figure 2 Flow chart of study procedures. CA, cystic artery; CD, cystic duct; CVS, critical view of safety; ICG, indocyanine
green.
Figure 3 Study timeline.
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administration of ICG, leave injection catheter or
cannula in the vein, keep airways free, inject 100–
300 mg hydrocortisone or a similar preparation by rapid
intravenous injection, substitute volume with isotonic
electrolyte solution, give oxygen and monitor the circu-
lation and slowly administer antihistamines intravenously.
In case of an anaphylactic shock, the patient will be
placed in the recumbent position with legs raised,
volume will be rapidly substituted with, for example, iso-
tonic electrolyte solution (pressure infusion), plasma
expanders. Furthermore, 0.1–0.5 mg epinephrine will be
administered and immediately diluted to 10 mL with
0.9% saline intravenously. If necessary, this will be
repeated after 10 min.
The beneﬁt for the patients in the NIRF-LC group will
possibly include a shorter period to the establishment of
CVS and the clearer identiﬁcation of CVS and its ana-
tomical components.
Do the individuals give informed consent?
To each patient, that is, a potential candidate for inclu-
sion, thorough patient information will be given. From
each individual who is willing to participate, written
informed consent will be obtained by one of the investi-
gators. The ethical issues of the trial will be thoroughly
explained and discussed, verbally and in writing. The
basic principles laid down in the Declaration of
Helsinki44 will be followed throughout the execution of
the trial. Accordingly, each participant has the right to
withdraw from the study at any given moment without
having to explain this decision in any way.
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